CGTX
Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-20.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 22, 2026 | Fletcher Aaron G.L. · director, 10 percent owner: | A-Award | 25,000 | $0.00 |
| Jun 22, 2026 | Khattar Jack A. · director | A-Award | 25,000 | $0.00 |
| Jun 22, 2026 | Monia Brett P · director | A-Award | 25,000 | $0.00 |
| Jun 22, 2026 | Wallace Peggy · director | A-Award | 25,000 | $0.00 |
| Jun 22, 2026 | RICHSTONE ELLEN B · director | A-Award | 25,000 | $0.00 |
| May 4, 2026 | Doyle John Brendan · officer: Chief Financial Officer | F-InKind | 8,567 | $1.28 |
| Apr 20, 2026 | Caggiano Anthony · officer: Chief Medical Officer | Purchase | 10,000 | $1.11 |
| Apr 20, 2026 | Doyle John Brendan · officer: Chief Financial Officer | Purchase | 10,000 | $1.13 |
| Apr 20, 2026 | Ricciardi Lisa · director, officer: CEO & President | Purchase | 9,175 | $1.10 |
| Feb 18, 2026 | Doyle John Brendan · officer: Chief Financial Officer | F-InKind | 1,560 | $1.12 |
| Feb 18, 2026 | Caggiano Anthony · officer: Chief Medical Officer | F-InKind | 4,680 | $1.12 |
| Feb 18, 2026 | Ricciardi Lisa · director, officer: CEO & President | F-InKind | 5,850 | $1.12 |
| Feb 5, 2026 | Doyle John Brendan · officer: Chief Financial Officer | F-InKind | 26,921 | $1.03 |
| Feb 5, 2026 | Ricciardi Lisa · director, officer: CEO & President | A-Award | 800,000 | $0.00 |
| Feb 5, 2026 | Ricciardi Lisa · director, officer: CEO & President | F-InKind | 26,036 | $1.12 |
| Feb 5, 2026 | Ricciardi Lisa · director, officer: CEO & President | F-InKind | 51,704 | $1.03 |
| Feb 5, 2026 | Doyle John Brendan · officer: Chief Financial Officer | A-Award | 200,000 | $0.00 |
| Feb 5, 2026 | Caggiano Anthony · officer: Chief Medical Officer | A-Award | 400,000 | $0.00 |
| Feb 5, 2026 | Caggiano Anthony · officer: Chief Medical Officer | F-InKind | 26,919 | $1.03 |
| Feb 5, 2026 | Caggiano Anthony · officer: Chief Medical Officer | F-InKind | 11,488 | $1.12 |
| Dec 22, 2025 | Doyle John Brendan · officer: Chief Financial Officer | F-InKind | 9,360 | $1.50 |
| Dec 22, 2025 | Ricciardi Lisa · director, officer: CEO & President | A-Award | 75,000 | $0.00 |
| Dec 22, 2025 | Ricciardi Lisa · director, officer: CEO & President | F-InKind | 23,400 | $1.50 |
| Dec 22, 2025 | Caggiano Anthony · officer: Chief Medical Officer | A-Award | 65,000 | $0.00 |
| Dec 22, 2025 | Caggiano Anthony · officer: Chief Medical Officer | F-InKind | 20,280 | $1.50 |
| Dec 22, 2025 | Doyle John Brendan · officer: Chief Financial Officer | A-Award | 30,000 | $0.00 |
| Sep 23, 2025 | Fletcher Aaron G.L. · director, 10 percent owner: | M-Exempt | 7,729 | $0.84 |
| Jul 31, 2025 | Ricciardi Lisa · director, officer: CEO & President | F-InKind | 23,400 | $0.67 |
| Jul 31, 2025 | Doyle John Brendan · officer: Chief Financial Officer | A-Award | 30,000 | $0.00 |
| Jul 31, 2025 | Caggiano Anthony · officer: Chief Medical Officer | F-InKind | 20,281 | $0.67 |
Institutional positioning
13F filings over the trailing two quarters
New 17Increased 41Reduced 26Sold out 13
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BIOS Capital Management, LP | Unchanged | 6,000,000 | Aug 14, 2026 |
| BIOS CAPITAL MANAGEMENT, LP | Unchanged | 6,000,000 | May 13, 2026 |
| DAVENPORT & Co LLC | Increased | 4,259,511 | Jul 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 3,438,775 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,001,787 | May 15, 2026 |
| DAVENPORT & CO LLC | Increased | 2,892,808 | Apr 15, 2026 |
| BlackRock, Inc. | Increased | 1,261,993 | Aug 7, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 1,117,136 | May 14, 2026 |
| Chescapmanager LLC | Unchanged | 997,029 | Aug 14, 2026 |
| CHESCAPMANAGER LLC | Unchanged | 997,029 | May 14, 2026 |
| BLACKROCK, INC. | Reduced | 968,362 | May 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 920,208 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | 910,006 | Aug 12, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Reduced | 693,288 | Aug 13, 2026 |
| HILTON CAPITAL MANAGEMENT, LLC | Unchanged | 548,950 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 22, 2026